オーストラリア - 英語 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - fluazuron; ivermectin - topical solution/suspension - fluazuron ungrouped active 15.0 g/l; ivermectin anthelmintic active 5.0 g/l - parasiticides - cattle - beef | bovine | bullocks | bulls | calves | cows | feedlot cattle | growers | heifer speyed | heifers (meat only) | pod - barber's pole worm - haemonchus placei | buffalo fly | cattle biting louse | cattle tick | cattle tick - see label resistant strain | external parasite | eyeworm - thelazia spp. | intestinal hair worm - t. colubriformis | intestinal threadworm - s. papillosus | large bowel worm - o. venulosum | lungworm - dictyocaulus viviparus | mite - chorioptes bovis | nodule worm - oesophagostomum radiatum | sarcoptes scabei var. bovis | shortnosed cattle louse | small brown stomach worm - o. ostertagi | small intestinal worm - cooperia spp. | stomach hair worm | sucking lice - linognathus vituli | thin necked intestinal worm | tubercle-bearing louse | whipworm - trichuris spp. | black scour worm | cattlebiting louse | chorioptic mange mite | damalinia bovis (old name) | ectoparasitic control | including inhibited stages | large lungworm | little blue sucking louse | short nosed sucking louse | ticks amidine resistant strain | ticks organophosphorus resista | ticks synthetic pyrethroid res

オーストラリア - 英語 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - ivermectin - parenteral liquid/solution/suspension - ivermectin anthelmintic active 10.0 mg/ml - parasiticides - cattle | pig - adult | beef | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | heifer | s - barber's pole worm - haemonchus placei | brown stomach worm - ostertagia lyrata | cattle tick | chorioptic mange mite | eyeworm - thelazia spp. | hookworm - bunostomum phlebotomum | hyostrongylus rubidus | intestinal hair worm - t. colubriformis | kidney worm | large intestinal roundworm - a. suum | large roundworm - toxocara vitulorum | lungworm | lungworm - metastrongylus spp. | mite | nematodirus helvetianus | nodule worm - oesophagostomum radiatum | oesophagostomum spp. - adult | pig louse | roundworm - strongyloides papillosus | sarcoptes scabei var. bovis | screw worm fly - chrysomya bezziana | shortnosed cattle louse | small brown stomach worm - o. ostertagi | small intestinal worm - cooperia spp. | stomach hair worm | strongyloides ransomi | sucking lice - linognathus vituli | thin necked intestinal worm-n. spathiger | tubercle-bearing louse | whipworm - trichuris spp. | whipworm - trichuris suis | black scour worm | gastrointestinal roundworm | including inhibited stages | intestinal threadworm | lar

オーストラリア - 英語 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

inca (flight) co pty ltd - oxytetracycline hydrochloride - oral powder, pre-mix - oxytetracycline hydrochloride antibiotic active 200.0 g/kg - antibiotic & related - birds - ornamental | cage birds | amazon parrot | caged bird | canary | cockatiel | cockatoo | conure | finch | lovebird | macaw - antibiotics - oral, parenteral | bacterial enteritis | chronic respiratory disease | airsacculitis | amoxycillin sensitive bacteria | anaerobic bacterial infection | avian mycoplasmas | clavulanic acid sensitive | coccidiosis | coryza | crd | dermatoses | diarrhoea | endometritis | enteritis | enzootic pneumonia | escherichia coli | european brood disease | gentamicin sensitive | hypermotility | infected wounds | infections | lactating | mastitis | post-weaning bacterial enterit | protozoal infections | pyometra | salmonellosis | sinusitis | systemic bacterial infection

オーストラリア - 英語 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - calcium as calcium gluconate; magnesium as magnesium hypophosphite; glucose; phosphorus - parenteral liquid/solution/suspension - calcium as calcium gluconate mineral-calcium-salt active 27.5 g/l; magnesium as magnesium hypophosphite mineral-magnesium active 4.7 g/l; glucose carbohydrate other 182.0 g/l; phosphorus mineral-phosphorus other 12.2 g/l - nutrition & metabolism - cattle | sheep | beef | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | ewe | heifer | h - grass tetany | milk fever | hypomagnesaemia | staggers

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - somatropin, quantity: 5 mg/ml - diluent, not applicable - excipient ingredients: metacresol; water for injections - short stature due to decreased or failed secretion of pituitary growth hormone. indications as at 20 march 2001: short stature due to decreased or failed secretion of pituitary hormone. growth distrubances associated with gonadal dysgenesis (turner's syndrome). improvement of body composition and treatment of short stature associated with prader-willi syndrome (pws) in paediatric patients. indications as at 26 november 2001: short stature due to decreased or failed secretion of pituitary growth hormone. treatment of adults with severe growth hormone deficiency as diagnosed in the insulin tolerance test for growth hormone deficiency and defined by peak growth hormone concentrations of less than 2.5 nanograms/ml. growth disturbances associated with gonadal dysgenesis (turner's syndrome). improvement of body composition and treatment of short stature associated with prader-willi syndrome (pws) in paediatric patients. indications as at 13 june 2003: short stature due to decreased or failed secretion of pituitary growth hormone. treatment of adults with severe growth hormone deficiency as diagnosed in the insulin tolerance test for growth hormone deficiency and defined by peak growth hormone concentrations of less than 2.5 nanogram/ml. growth disturbances associated with gonadal dysgenesis (turner's syndrome). improvement of body composition and treatment of short stature associated with prader-willi syndrome (pws) in paediatric patients. for treatment of growth disturbance in children with chronic renal insufficiency whose height is on or less than twenty-fifth percentile and whose growth velocity is on or less than twenty-fifth percentile for bone age. chronic renal insufficiency is defined as glomerular filtration rate of less than 50 ml/min/1.73m2.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - somatropin, quantity: 12 mg/ml - injection, powder for - excipient ingredients: glycine; mannitol; monobasic sodium phosphate; dibasic sodium phosphate - short stature due to decreased or failed secretion of pituitary growth hormone. treatment of adults with severe growth hormone deficiency as diagnosed in the insulin tolerance test for growth hormone deficiency and defined by peak growth hormone concentrations of less than 2.5 nanogram/ml. growth disturbances associated with gonadal dysgenesis (turner's syndrome). improvement of body composition and treatment of short stature associated with prader-willi syndrome (pws) in paediatric patients. for treatment of growth disturbance in children with chronic renal insufficiency whose height is on or less than twenty-fifth percentile and whose growth velocity is on or less than twenty-fifth percentile for bone age. chronic renal insufficiency is defined as glomerular filtration rate of less than 50 ml/min/1.73m2.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - somatropin, quantity: 5 mg/ml - injection, powder for - excipient ingredients: glycine; mannitol; monobasic sodium phosphate; dibasic sodium phosphate - short stature due to decreased or failed secretion of pituitary growth hormone. treatment of adults with severe growth hormone deficiency as diagnosed in the insulin tolerance test for growth hormone deficiency and defined by peak growth hormone concentrations of less than 2.5 nanogram/ml. growth disturbances associated with gonadal dysgenesis (turner's syndrome). improvement of body composition and treatment of short stature associated with prader-willi syndrome (pws) in paediatric patients. for treatment of growth disturbance in children with chronic renal insufficiency whose height is on or less than twenty-fifth percentile and whose growth velocity is on or less than twenty-fifth percentile for bone age. chronic renal insufficiency is defined as glomerular filtration rate of less than 50 ml/min/1.73m2.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - somatropin, quantity: 8 mg/ml - injection, solution - excipient ingredients: phenol; sucrose; citric acid; poloxamer; water for injections; sodium hydroxide - saizen is indicated for:,1. treatment of growth failure in children due to human growth hormone deficiency.,2. treatment of growth failure in girls with gonadal dysgenesis (turner syndrome), confirmed by chromosomal analysis.,3. replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in 2 different dynamic tests for growth hormone deficiency and defind by peak gh concentrations of less than 2.5 nanogram/ml. adults must also fulfill the following criteria: childhood onset: patients who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with saizen is started. adult onset: patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin.,4. treatment of growth disturbance (growth retardation) in pre-pubertal children due to chronic renal insufficiency (cri).

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - somatropin, quantity: 8 mg/ml - injection, solution - excipient ingredients: sucrose; poloxamer; sodium hydroxide; water for injections; citric acid; phenol - saizen is indicated for:,1. treatment of growth failure in children due to human growth hormone deficiency.,2. treatment of growth failure in girls with gonadal dysgenesis (turner syndrome), confirmed by chromosomal analysis.,3. replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in 2 different dynamic tests for growth hormone deficiency and defind by peak gh concentrations of less than 2.5 nanogram/ml. adults must also fulfill the following criteria: childhood onset: patients who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with saizen is started. adult onset: patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin.,4. treatment of growth disturbance (growth retardation) in pre-pubertal children due to chronic renal insufficiency (cri).

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - somatropin, quantity: 5.83 mg/ml - injection, solution - excipient ingredients: poloxamer; sodium hydroxide; sucrose; citric acid; phenol; water for injections - saizen is indicated for:,1. treatment of growth failure in children due to human growth hormone deficiency.,2. treatment of growth failure in girls with gonadal dysgenesis (turner syndrome), confirmed by chromosomal analysis.,3. replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in 2 different dynamic tests for growth hormone deficiency and defind by peak gh concentrations of less than 2.5 nanogram/ml. adults must also fulfill the following criteria: childhood onset: patients who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with saizen is started. adult onset: patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin.,4. treatment of growth disturbance (growth retardation) in pre-pubertal children due to chronic renal insufficiency (cri).